Gloom Over Prospects For Brexit Trade Deal
Trade, IP And Northern Ireland Protocol High On BIA Agenda
Executive Summary
With time running out on the UK-EU trade deal negotiations, the UK life sciences industry looks at the fine print of the new guidance on medicines regulation and explains why a mutual recognition agreement is urgently needed.
You may also be interested in...
Brexit: Medicine Supplies Face ‘Significant Disruption’ At Ports
As negotiators struggle to reach agreement on the future UK/EU relationship, pharma firms have been warned to expect major hold-ups next year for medicines crossing the Channel.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.